Induced pluripotent stem cells: the new patient? - PubMed (original) (raw)

Review

. 2012 Nov;13(11):713-26.

doi: 10.1038/nrm3448. Epub 2012 Oct 4.

Affiliations

Review

Induced pluripotent stem cells: the new patient?

Milena Bellin et al. Nat Rev Mol Cell Biol. 2012 Nov.

Abstract

Worldwide increases in life expectancy have been paralleled by a greater prevalence of chronic and age-associated disorders, particularly of the cardiovascular, neural and metabolic systems. This has not been met by commensurate development of new drugs and therapies, which is in part owing to the difficulty in modelling human diseases in laboratory assays or experimental animals. Patient-specific induced pluripotent stem (iPS) cells are an emerging paradigm that may address this. Reprogrammed somatic cells from patients are already applied in disease modelling, drug testing and drug discovery, thus enabling researchers to undertake studies for treating diseases 'in a dish', which was previously inconceivable.

PubMed Disclaimer

References

    1. PLoS One. 2011;6(9):e25255 - PubMed
    1. Science. 2008 Aug 29;321(5893):1218-21 - PubMed
    1. Nature. 2011 Mar 10;471(7337):225-9 - PubMed
    1. Cell Stem Cell. 2009 May 8;4(5):381-4 - PubMed
    1. Blood. 2011 Jan 20;117(3):839-47 - PubMed

Publication types

MeSH terms

LinkOut - more resources